howdy yd, interestingly Wilsons brought this up,
"Acquired resistance to these anti-PD-1/L1 therapies
is a key issue the industry is attempting to combat with rates climbing north of 50% of patients by ~24months of therapy "
Keytruda etc already have issues for people with low PD1/L1 expression rates where immutep hope EFTI can help,
potential market for EFTI may be broader than we thought...
howdy yd, interestingly Wilsons brought this up,"Acquired...
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.0¢ |
Change
-0.010(2.94%) |
Mkt cap ! $480.0M | |||
| Open | High | Low | Value | Volume |
| 33.0¢ | 33.5¢ | 32.0¢ | $1.703M | 5.215M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 211685 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.5¢ | 279000 | 3 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |